Cardiff Oncology to Present at Upcoming Investor Conferences in September

SAN DIEGO, Sept. 5, 2023 /PRNewswire/ — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that company management will…

About the Author

has written 41538 stories on this site.

Copyright © 2010 Business and Corporate News.